Discontinuing Aripiprazole LAI After Two Monthly Doses
Simply stop the injections without any oral supplementation or tapering—the long-acting formulation will gradually decline over several weeks, providing a built-in taper. 1
Rationale for Abrupt Discontinuation
The pharmacokinetic properties of aripiprazole once-monthly 400 mg make formal tapering unnecessary. After the last injection, aripiprazole levels decline gradually over 4-6 weeks due to the depot formulation's extended-release mechanism. This creates a natural tapering effect that minimizes withdrawal symptoms.
Since your patient:
- Was not on oral aripiprazole before starting the LAI
- Has only received two doses (minimal exposure)
- Wants to discontinue
The approach is straightforward: discontinue the injection and monitor.
Monitoring After Discontinuation
Watch for:
- Return of original psychiatric symptoms (psychosis, mood instability, agitation) over the next 4-8 weeks as medication levels decline
- Withdrawal symptoms are uncommon with aripiprazole but monitor for insomnia, nausea, or anxiety in the first 2-3 weeks
- Akathisia or movement disorders may paradoxically improve or worsen temporarily 1
Clinical Considerations
Do NOT:
- Add oral aripiprazole for tapering (unnecessary and prolongs exposure)
- Use cross-titration with another antipsychotic unless clinically indicated for the underlying condition
- Expect immediate symptom changes—the medication remains active for weeks
Common pitfall: Providers sometimes add oral aripiprazole when discontinuing the LAI, but this is only indicated when continuing aripiprazole therapy, not when stopping it entirely 1.
Special Circumstances
If the patient develops significant symptom recurrence during the natural decline phase (weeks 2-6 post-last injection), this represents the underlying condition re-emerging rather than withdrawal. At that point, consider:
- Restarting treatment (LAI or oral, based on shared decision-making)
- Alternative antipsychotic if aripiprazole was ineffective or poorly tolerated
- Reassessment of diagnosis and contributing factors 2
The FDA labeling confirms that abrupt discontinuation is safe—no specific tapering protocol is required for aripiprazole LAI 1. The gradual pharmacokinetic decline provides inherent protection against withdrawal phenomena.